Skip to content
DraconiticResearch
Search Sources API
186,123 studies31 sourcesUpdated 45 min ago
PreprintCC BY-NC-NDbioRxiv

LINC00536 regulates transcriptional repressor TRPS1 in breast cancer

  1. 1Research Institute McGill University Health Center,

Abstract

Metastatic breast cancer with complex molecular mechanisms of progression accounts for most cancer related deaths in women. To improve diagnosis and drug development, it is important to identify novel biomarkers and critical molecular pathways involved in tumor initiation and progression. Here, we profiled and analyzed the expression of long non-coding RNAs (lncRNAs) from three distinct stages of tumor initiation and progression (hyperplasia, adenoma, and carcinoma). We performed RNAseq on tumor and mammary epithelial cells derived from ROSAmT/mG tumor and non-tumor mice. We identified 1913 differentially expressed protein coding genes and 324 lncRNAs in breast cancer cells of all stages compared with normal mammary epithelial cells. Pearson correlation analysis correlated 93 differentially expressed lncRNAs with protein coding genes, providing a comprehensive lncRNA-protein coding genes co-expression network. Among them, we focused on Gm19303 which was paired with the differentially expressed protein coding gene, transcriptional repressor GATA binding 1 (Trps1), and identified its human counterpart as LINC00536. Both LINC00536 and TRPS1 are only overexpressed in breast cancer and correlate with poor prognosis of patient from the TCGA and GTEx databases. Single cell RNAseq data from the Atlas of Human breast cancers further confirmed that TRPS1 is upregulated in human breast cancer compared to normal human mammary tissue with highest expression in ER+ subgroup. In summary, our study explored the potential role of lncRNAs in breast cancer initiation and progression. *Implications statement: Our findings imply that human LINC00536/TRPS1 serves as a novel and early biomarker of cancer progression and a potential therapeutic target for breast cancer.

Related

  1. PTP1B supports survival and regulates CFL1 and HSP90a abundance in trastuzumab-resistant HER2-positive breast cancer.
    V. Mandati, M. C. Panepinto, C. Felice +7
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  2. ZBTB1 Regulates Glycolysis and Chemotherapy Resistance Through Interacting with c-Myc in Triple Negative Breast Cancer
    Na Qian, Songyao Sun, Cong Ouyang +10
    CancersPeer-reviewedCC BYFull textOncologyEurope PMC
  3. The atypical cadherin CELSR2 regulates distinct epithelial-mesenchymal states and oxidative phosphorylation in triple-negative breast cancer
    J. Koren, N.-I. Y. Saidani, A. El kaoutari +13
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  4. CST1 Regulates ER-Mitochondrial Mg²⁺ Balance via MAGT1 to Promote Breast Cancer Metabolism and Growth.
    Wenqiang Gan, Min Zheng, Li Liu +8
    International journal of biological sciencesPeer-reviewedCC BYFull textOncologyEurope PMC
  5. CXCR5 regulates CD8+/GZMB+ T cell infiltration and apoptotic signaling in breast cancer
    Weihong Feng, Jin Yan, Xue Gong +4
    iSciencePeer-reviewedCC BY 4.0Full textImmunologyOncologyCell PressCrossrefEurope PMCEurope PMC+1
BibTeX
@misc{zhang2026linc00536,
  title = {{LINC00536 regulates transcriptional repressor TRPS1 in breast cancer}},
  author = {R. Zhang and J. Li and D. Badescu and I. Ragoussis and R. Kremer},
  howpublished = {bioRxiv},
  year = {2026},
  month = aug,
  doi = {10.64898/2026.08.31.748275},
  url = {https://www.biorxiv.org/content/10.64898/2026.08.31.748275v1},
  note = {CC BY-NC-ND},
}
RIS
TY  - UNPB
TI  - LINC00536 regulates transcriptional repressor TRPS1 in breast cancer
AU  - R. Zhang
AU  - J. Li
AU  - D. Badescu
AU  - I. Ragoussis
AU  - R. Kremer
PY  - 2026
DA  - 2026/08/31
PB  - bioRxiv
DO  - 10.64898/2026.08.31.748275
UR  - https://www.biorxiv.org/content/10.64898/2026.08.31.748275v1
AB  - Metastatic breast cancer with complex molecular mechanisms of progression accounts for most cancer related deaths in women. To improve diagnosis and drug development, it is important to identify novel biomarkers and critical molecular pathways involved in tumor initiation and progression. Here, we profiled and analyzed the expression of long non-coding RNAs (lncRNAs) from three distinct stages of tumor initiation and progression (hyperplasia, adenoma, and carcinoma). We performed RNAseq on tumor and mammary epithelial cells derived from ROSAmT/mG tumor and non-tumor mice. We identified 1913 differentially expressed protein coding genes and 324 lncRNAs in breast cancer cells of all stages compared with normal mammary epithelial cells. Pearson correlation analysis correlated 93 differentially expressed lncRNAs with protein coding genes, providing a comprehensive lncRNA-protein coding genes co-expression network. Among them, we focused on Gm19303 which was paired with the differentially expressed protein coding gene, transcriptional repressor GATA binding 1 (Trps1), and identified its human counterpart as LINC00536. Both LINC00536 and TRPS1 are only overexpressed in breast cancer and correlate with poor prognosis of patient from the TCGA and GTEx databases. Single cell RNAseq data from the Atlas of Human breast cancers further confirmed that TRPS1 is upregulated in human breast cancer compared to normal human mammary tissue with highest expression in ER+ subgroup. In summary, our study explored the potential role of lncRNAs in breast cancer initiation and progression. *Implications statement: Our findings imply that human LINC00536/TRPS1 serves as a novel and early biomarker of cancer progression and a potential therapeutic target for breast cancer.
ER  -